Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-08-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于收到要约收购报告书摘要的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 哈药集团股份有限公司 regarding the receipt of a summary of a tender offer report (要约收购报告书摘要). It details the background of a capital increase in the controlling shareholder 哈药集团, the resulting changes in shareholding structure, and the obligation to make a comprehensive tender offer to other shareholders. The document includes specifics about the offer price, number of shares to be acquired, funding sources, and legal compliance. It is not the full tender offer report itself but a summary and a notice to investors about the tender offer and related corporate actions. The document length is 2427 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a tender offer and capital structure change but does not contain the full detailed report or financial statements. It is not a full M&A filing or merger proxy statement, nor a full capital/financing update report, but a regulatory announcement of the tender offer summary and related corporate actions.
2019-08-14 Chinese
要约收购报告书摘要
M&A Activity Classification · 95% confidence The document is titled as a "要约收购报告书摘要" which translates to "Summary of Tender Offer Report" or "Offer to Purchase Report Summary." It details a comprehensive tender offer by 哈药集团有限公司 (Harbin Pharmaceutical Group Co., Ltd.) to acquire shares of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd. listed company). The document includes detailed information about the offer, the acquirer, the target company, the shareholding structure, the purpose of the offer, the funding, and the legal and regulatory approvals involved. It references relevant securities laws and regulations, and the document is lengthy (15,000 characters), indicating it is the actual report rather than a brief announcement. This type of document corresponds to filings related to merger and acquisition activities, specifically tender offers and takeover bids. According to the provided filing definitions, this fits best under "M&A Activity" (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. It is not a simple announcement or a proxy solicitation, but a detailed offer document. Therefore, the correct classification is TAR with high confidence.
2019-08-14 Chinese
重大事项提示性公告
M&A Activity Classification · 95% confidence The document is a short announcement (605 characters) from the board of 哈药集团股份有限公司 regarding a significant event: a change in controlling shareholders due to capital increase and introduction of new investors, leading to a change in actual control. It also mentions the initiation of a tender offer (要约收购) process and that further announcements will follow. The document does not contain financial statements or detailed financial data, nor is it a full report. It is a regulatory announcement about a major corporate event related to ownership and control changes, specifically a tender offer initiation. This fits best under the category of M&A Activity (TAR), which covers announcements related to merger proposals or takeover bids. The document is not a full merger filing (MA), but an announcement of the tender offer process starting, which aligns with TAR. Confidence is high due to clear mention of tender offer and control change.
2019-08-13 Chinese
君合律师事务所关于哈药集团有限公司增资完成后实际控制人认定事宜之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the identification of the actual controller of Harbin Pharmaceutical Group Co., Ltd. after a capital increase. It includes detailed legal analysis, references to investment agreements, joint venture contracts, shareholder declarations, and government approvals. The document is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to corporate control and shareholder structure following a capital increase. This fits the definition of an Audit Report / Information (AR) category, which includes applied accounting principles and regulatory or internal assessments excluding full annual reports. The document is 6357 characters long, contains substantive content, and is not merely an announcement or certification. Therefore, the best classification is AR with high confidence.
2019-08-12 Chinese
重大事项提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (630 characters) regarding a significant change in the controlling shareholder and potential mandatory tender offer obligations. It discusses a major event affecting company control and warns investors about risks. It does not contain financial statements or detailed financial data, nor is it a full report. It is not a certification or a voting result announcement. It is a regulatory announcement about a material event affecting shareholding and control. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant corporate event.
2019-08-12 Chinese
关于控股股东权益变动的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a change in the controlling shareholder's equity structure of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It describes the introduction of new investors through capital increase, changes in shareholding percentages, and the resulting change in actual control of the company. The document includes specifics about the new shareholders, the capital increase agreement, and the impact on the company's control. It is a formal announcement of a significant change in shareholding and control, but it does not contain financial statements, earnings data, or audit information. It is not a full annual or interim report, nor is it a simple notice of dividend or voting results. The content fits best with a Capital/Financing Update (CAP) as it details fundraising activities and changes in capital structure through equity investment.
2019-08-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.